STAT3 and thyroid gland carcinoma: Metformin shows potential therapeutic value by inhibiting the mTOR signaling pathway and targeting JAK2 in the JAK2/STAT3 signaling pathway, thereby effectively inhibiting the proliferation, migration, and EMT of thyroid cancer cell lines (142, 143).